Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).
Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ. Germann UA, et al. Among authors: boucher dm. Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22. Mol Cancer Ther. 2017. PMID: 28939558
Cancer stem cells as the relevant biomass for drug discovery.
Winquist RJ, Furey BF, Boucher DM. Winquist RJ, et al. Among authors: boucher dm. Curr Opin Pharmacol. 2010 Aug;10(4):385-90. doi: 10.1016/j.coph.2010.06.008. Epub 2010 Jul 12. Curr Opin Pharmacol. 2010. PMID: 20630801 Review.
Proof of Principle for Local Delivery of a c-Met Inhibitor.
Li H, Kadiyala I, Briggs M, Shawgo R, Reda K, Patel R, Tanner K, Berlioz-Seux F, Furey B, Hurter P, Boucher DM. Li H, et al. Among authors: boucher dm. J Pharm Sci. 2018 Mar;107(3):856-862. doi: 10.1016/j.xphs.2017.10.025. Epub 2017 Oct 26. J Pharm Sci. 2018. PMID: 29107043
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR. Hall AB, et al. Among authors: boucher dm. Oncotarget. 2014 Jul 30;5(14):5674-85. doi: 10.18632/oncotarget.2158. Oncotarget. 2014. PMID: 25010037 Free PMC article.
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.
Tang Q, Aronov AM, Deininger DD, Giroux S, Lauffer DJ, Li P, Liang J, McGinty K, Ronkin S, Swett R, Waal N, Boucher D, Ford PJ, Moody CS. Tang Q, et al. ACS Med Chem Lett. 2021 May 24;12(6):955-960. doi: 10.1021/acsmedchemlett.1c00094. eCollection 2021 Jun 10. ACS Med Chem Lett. 2021. PMID: 34141080 Free PMC article.
Factors influencing development of new therapeutics for oncology.
Winquist RJ, Boucher DM. Winquist RJ, et al. Among authors: boucher dm. Curr Opin Pharmacol. 2010 Aug;10(4):353-5. doi: 10.1016/j.coph.2010.06.011. Epub 2010 Jul 14. Curr Opin Pharmacol. 2010. PMID: 20634136 No abstract available.
27 results